Funding

Star Therapeutics

United States · Biotech

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

Visit star-therapeutics.comFunding history

Product

Star Therapeutics discovers and develops therapies for diseases with substantial unmet need. Its team’s work spans antibody medicines and programs in hematology and immunology.

Based in South San Francisco, the company is advancing a new pipeline after Incyte acquired its Vega Therapeutics subsidiary in July 2026. Its October private financing will support clinical development and additional programs.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Private financing$200MJanus Henderson Investors — LeadOrbiMed — Lead

Investors

Janus Henderson InvestorsLed Private financingOrbiMedLed Private financing

Coverage

Oct 23, 2026Star Therapeutics · Private financing

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
SEGNOSSEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.Undisclosed · Pre-Series A
Sourcesstar-therapeutics.com ↗